Find Clinical Trials

← Back
July 14, 2025 in Gastrointestinal (GI)

LUCERNA 8951-CL-0305

A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction…
Read More
February 19, 2025 in Gastrointestinal (GI)

S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

Read More
October 9, 2024 in Gastrointestinal (GI)

S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE) (NCT 06203600)
Read More
May 29, 2024 in Gastrointestinal (GI)

A022106

Phase II/III second-line NABPLAGEM vs. nab-paclitaxel/gemcitabine in BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM)
Read More
March 11, 2024 in Gastrointestinal (GI)

A022004

Randomized trial of consolidation targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer
Read More
May 31, 2023 in Gastrointestinal (GI)

A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASUR)
Read More
April 24, 2023 in Gastrointestinal (GI)

A022102

A022102: A Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
Read More
February 14, 2023 in Gastrointestinal (GI)

EA2192: APOLLO

A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Read More
October 14, 2022 in Gastrointestinal (GI)

SGNTUC-029

An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with…
Read More
September 14, 2022 in Gastrointestinal (GI)

GI003

GI003: A Phase III Randomized Trial of Protons Versus Photons For Hepatocellular Carcinoma
Read More
July 11, 2022 in Gastrointestinal (GI)

WF1806

WF-1806: Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M and M Study (NCT03998202)
Read More
July 11, 2022 in Gastrointestinal (GI)

S2001

S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
Read More
July 11, 2022 in Gastrointestinal (GI)

S1922

S1922: Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Read More
June 30, 2022 in Gastrointestinal (GI)

GI008

GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NCT 05174169)
Read More
June 30, 2022 in Gastrointestinal (GI)

GI006

GI006: Phase III Randomized Trial of Proton Beam Therapy (PBT) versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Read More
June 30, 2022 in Gastrointestinal (GI)

GI005

GI005: Phase II/III study of Circulating tumor DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA)
Read More
June 30, 2022 in Gastrointestinal (GI)

GI004

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch…
Read More
June 30, 2022 in Gastrointestinal (GI)

EA2187

*Study Suspended 3/31/21.  EA2187: A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Read More
June 30, 2022 in Gastrointestinal (GI)

EA2186

EA2186, A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT) (NCT)
Read More